Eight genes (CHGA, CPE, ENO2, INSM1, PTPRN2, SERPINA10, and SLC18A1/2) that have been previously identified as markers of neuroendocrine tumors [28]–[31] were confirmed in this study to be altered. The gene discussed is ENO2; the disease is neuroendocrine neoplasm.